Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.

Literature DB >> 18955522

In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.

Kaori Tanaka¹, Hiroshige Mikamo, Kenichi Nakao, Taku Ichiishi, Takatsugu Goto, Yuka Yamagishi, Kunitomo Watanabe.

Abstract

The antianaerobic activity of tomopenem, a new longer-half-life parenteral carbapenem, was compared with other carbapenems. Tomopenem showed broad activity against 63 reference species. The activity of tomopenem against 293 clinical isolates was potent (MIC(90), 0.06 to 4 microg/ml) and comparable to those of meropenem and doripenem and more potent than that of panipenem.

Entities: Chemical

Mesh：

Substances：

Year: 2008 PMID： 18955522 PMCID： PMC2612141 DOI： 10.1128/AAC.00595-08

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.

Authors: D M Livermore; M W Carter; S Bagel; B Wiedemann; F Baquero; E Loza; H P Endtz; N van Den Braak; C J Fernandes; L Fernandes; N Frimodt-Moller; L S Rasmussen; H Giamarellou; E Giamarellos-Bourboulis; V Jarlier; J Nguyen; C E Nord; M J Struelens; C Nonhoff; J Turnidge; J Bell; R Zbinden; S Pfister; L Mixson; D L Shungu
Journal: Antimicrob Agents Chemother Date: 2001-06 Impact factor: 5.191

2. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa.

Authors: Kenneth S Thomson; Ellen Smith Moland
Journal: J Antimicrob Chemother Date: 2004-06-16 Impact factor: 5.790

3. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

Authors: J G Sundelof; R Hajdu; C J Gill; R Thompson; H Rosen; H Kropp
Journal: Antimicrob Agents Chemother Date: 1997-08 Impact factor: 5.191

4. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.

Authors: Takahiro Shibayama; Yoko Matsushita; Takashi Hirota; Toshihiko Ikeda; Shogo Kuwahara
Journal: Antimicrob Agents Chemother Date: 2006-10-16 Impact factor: 5.191

5. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.

Authors: Tetsufumi Koga; Tomomi Abe; Harumi Inoue; Takashi Takenouchi; Akiko Kitayama; Tatsuhiko Yoshida; Nobuhisa Masuda; Chika Sugihara; Masayo Kakuta; Miyuki Nakagawa; Takahiro Shibayama; Yoko Matsushita; Takashi Hirota; Satoshi Ohya; Yukio Utsui; Takashi Fukuoka; Syogo Kuwahara
Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191

6. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes.

Authors: Kenneth E Aldridge
Journal: Diagn Microbiol Infect Dis Date: 2002-10 Impact factor: 2.803

7. Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections.

Authors: Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen Fernandez
Journal: Antimicrob Agents Chemother Date: 2002-04 Impact factor: 5.191

8. Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.

Authors: Takahiro Shibayama; Yoko Matsushita; Kenji Kawai; Takashi Hirota; Toshihiko Ikeda; Shogo Kuwahara
Journal: Antimicrob Agents Chemother Date: 2006-10-30 Impact factor: 5.191

9. Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety.

Authors: Isao Kawamoto; Yasuo Shimoji; Osamu Kanno; Katsuhiko Kojima; Katsuya Ishikawa; Emi Matsuyama; Yuka Ashida; Takahiro Shibayama; Takashi Fukuoka; Satoshi Ohya
Journal: J Antibiot (Tokyo) Date: 2003-06 Impact factor: 2.649

In vitro activity of tomopenem (CS-023/RO4908463) against anaerobic bacteria.

1. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.

2. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa.

3. Pharmacokinetics of L-749,345, a long-acting carbapenem antibiotic, in primates.

4. Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.

5. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.

6. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes.

7. Comparative in vitro activities of ertapenem (MK-0826) against 469 less frequently identified anaerobes isolated from human infections.

8. Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.

9. Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety.

Review 10. In vitro activity of ertapenem: review of recent studies.

Review 1. Anaerobic infections: update on treatment considerations.

Review 2. Advances in MRSA drug discovery: where are we and where do we need to be?

3. Bis-Cyclic Guanidines as a Novel Class of Compounds Potent against Clostridium difficile.

Review 4. Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.